{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T01:01:07Z","timestamp":1755219667839,"version":"3.43.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"am","delay-in-days":346,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.clgc.2025.102339","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T11:58:04Z","timestamp":1743335884000},"page":"102339","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Significance of Body Surface Area Correction for Cisplatin Eligibility Based on Renal Function of Patients With Muscle-Invasive Bladder Cancer"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6256-4352","authenticated-orcid":false,"given":"Yushi","family":"Naito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Tochigi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0484-4513","authenticated-orcid":false,"given":"Noritoshi","family":"Shamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaichi","family":"Sugihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohei","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshie","family":"Kanada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotaka","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6239-2917","authenticated-orcid":false,"given":"Jun","family":"Nagayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihisa","family":"Matsukawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shusuke","family":"Akamatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2025.102339_bib0001","unstructured":"EAU Guidelines. Edn presented at the EAU Annual Congress Milan. ISBN 978-94-92671-19-6; 2023. https:\/\/uroweb.org\/guidelines\/muscle-invasive-and-metastatic-bladder-cancer. Accessed August 2, 2024."},{"key":"10.1016\/j.clgc.2025.102339_bib0002","unstructured":"National Comprehensive Cancer Network. Bladder cancer (Version 4.2024). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bladder.pdf. Accessed August 2, 2024."},{"issue":"11","key":"10.1016\/j.clgc.2025.102339_bib0003","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.clgc.2025.102339_bib0004","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.clgc.2025.102339_bib0005","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clgc.2025.102339_bib0006","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.eururo.2008.10.016","article-title":"Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer","volume":"55","author":"Calabr\u00f2","year":"2009","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.clgc.2025.102339_bib0007","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clgc.2025.102339_bib0008","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3233\/BLC-190235","article-title":"Cisplatin ineligibility for patients with metastatic urothelial carcinoma: a survey of clinical practice perspectives among US oncologists","volume":"5","author":"Galsky","year":"2019","journal-title":"BlC"},{"issue":"1","key":"10.1016\/j.clgc.2025.102339_bib0009","first-page":"465","article-title":"Standardization of chemotherapy and individual dosing of platinum compounds","volume":"34","author":"Puisset","year":"2014","journal-title":"Anticancer Res"},{"issue":"3","key":"10.1016\/j.clgc.2025.102339_bib0010","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/cncr.22031","article-title":"Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder","volume":"107","author":"Dash","year":"2006","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.clgc.2025.102339_bib0011","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/annonc\/mdx692","article-title":"Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a retrospective international study of invasive\/advanced cancer of the urothelium (RISC)","volume":"29","author":"Bamias","year":"2018","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2025.102339_bib0012","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.eururo.2020.08.024","volume":"79","author":"Pfister","year":"2021","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.clgc.2025.102339_bib0013","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s10157-023-02415-0","article-title":"Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022","volume":"28","author":"Yanagita","year":"2024","journal-title":"Clin Exp Nephrol"},{"issue":"5","key":"10.1016\/j.clgc.2025.102339_bib0014","first-page":"576","article-title":"A modified Cockcroft-Gault formula taking into account the body surface area gives a more accurate estimation of the glomerular filtration rate","volume":"20","author":"Rostoker","year":"2007","journal-title":"J Nephrol"},{"year":"2017","series-title":"TNM Classification of Malignant Tumours","key":"10.1016\/j.clgc.2025.102339_bib0015"},{"key":"10.1016\/j.clgc.2025.102339_bib0016","unstructured":"US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE). V.5.0. Cancer Ther Eval Progr. Published online; 2017:1-155. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5\u00d77.pdf."},{"issue":"4","key":"10.1016\/j.clgc.2025.102339_bib0017","doi-asserted-by":"crossref","first-page":"c179","DOI":"10.1159\/000339789","article-title":"KDIGO clinical practice guidelines for acute kidney injury","volume":"120","author":"Khwaja","year":"2012","journal-title":"Nephron Clin Pract"},{"issue":"3","key":"10.1016\/j.clgc.2025.102339_bib0018","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"17","key":"10.1016\/j.clgc.2025.102339_bib0019","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"von der Maase","year":"2000","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clgc.2025.102339_bib0020","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1200\/JCO.2001.19.10.2638","volume":"19","author":"Sternberg","year":"2001","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2025.102339_bib0021","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0022-5347(17)42494-3","article-title":"M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium","volume":"139","author":"Sternberg","year":"1988","journal-title":"J Urol"},{"issue":"22","key":"10.1016\/j.clgc.2025.102339_bib0022","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant Nivolumab versus Placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clgc.2025.102339_bib0023","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/01.ju.0000162039.38023.5f","article-title":"Update on chemotherapy for advanced bladder cancer","volume":"174","author":"Rosenberg","year":"2005","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.clgc.2025.102339_bib0024","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1053\/j.ajkd.2014.04.010","article-title":"Measuring GFR: a systematic review","volume":"64","author":"Soveri","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1016\/j.clgc.2025.102339_bib0025","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00280-016-2966-1","article-title":"Validity of new methods to evaluate renal function in cancer patients treated with cisplatin","volume":"77","author":"Funakoshi","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102339_bib0026","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.clgc.2011.10.004","article-title":"Impact of the CKD-EPI equation for estimating renal function on eligibility for cisplatin-based chemotherapy in patients with urothelial cancer","volume":"10","author":"Tsao","year":"2012","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"10.1016\/j.clgc.2025.102339_bib0027","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S1470-2045(10)70275-8","article-title":"A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy","volume":"12","author":"Galsky","year":"2011","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.clgc.2025.102339_bib0028","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1016\/j.ejca.2012.04.002","article-title":"Cisplatin and gemcitabine administered every two weeks in patients with locally advanced or metastatic urothelial carcinoma and impaired renal function","volume":"48","author":"Morales-Barrera","year":"2012","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.clgc.2025.102339_bib0029","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1093\/annonc\/mdr156","article-title":"Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma","volume":"23","author":"Galsky","year":"2012","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.clgc.2025.102339_bib0030","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.21873\/invivo.12569","article-title":"Modification of platinum-based systemic chemotherapy for advanced urothelial carcinoma in patients with suboptimal renal function","volume":"35","author":"Hamada","year":"2021","journal-title":"In Vivo"},{"issue":"9","key":"10.1016\/j.clgc.2025.102339_bib0031","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/jjco\/hyv082","article-title":"Impact of renal function of patients with advanced urothelial cancer on eligibility for first-line chemotherapy and treatment outcomes","volume":"45","author":"Ichioka","year":"2015","journal-title":"Jpn J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2025.102339_bib0032","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2215\/CJN.11721018","article-title":"Estimation of kidney function in oncology: implications for anticancer drug selection and dosing","volume":"14","author":"Casal","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"34","key":"10.1016\/j.clgc.2025.102339_bib0033","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1200\/JCO.18.01148","article-title":"Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study","volume":"36","author":"Necchi","year":"2018","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clgc.2025.102339_bib0034","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1634\/theoncologist.2019-0851","article-title":"Prognostic value of DNA damage response genomic alterations in relapsed\/advanced urothelial cancer","volume":"25","author":"Yin","year":"2020","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.clgc.2025.102339_bib0035","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur Urol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325000400?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325000400?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T07:25:28Z","timestamp":1754551528000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767325000400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1558767325000400"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102339","relation":{},"ISSN":["1558-7673"],"issn-type":[{"type":"print","value":"1558-7673"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Significance of Body Surface Area Correction for Cisplatin Eligibility Based on Renal Function of Patients With Muscle-Invasive Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102339","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102339"}}